Abstract
Cardiovascular diseases (CVDs) have become a predominant cause of death worldwide. Although CVDs encompass a variety of pathological conditions that affect the heart and blood vasculature, they can be classified into two major groups according to their basic pathophysiologic mechanisms, namely atherosclerosis and aneurysm formation. Increasing evidence implicates micro-RNAs (miRNAs or miRs) as vital factors both in the initiation and progression processes of CVDs. Some miRs have a promoting role in CVD development, while others have a protective role. Today, miRs have been shown to be potential biomarkers for several types of CVDs, while strategies targeting miRs are under consideration as potential tools for exploitation in therapeutic approaches for CVD treatments. In this review, we present the available data on the involvement of miRs in CVDs, focusing on their role as regulators of the inflammatory process as an initiating and driving component of CVDs.
Keywords: Biomarkers, cardiovascular disease, inflammation, miRNAs.
Current Medicinal Chemistry
Title:MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets
Volume: 22 Issue: 22
Author(s): Athanassios Kotsinas, Fragkiska Sigala, Spiros D. Garbis, Giorgos Galyfos, Konstantinos Filis, Konstantinos Vougas, Alexandros Papalampros, Elizabeth E. Johnson, Efstathios Chronopoulos, Alexandros G. Georgakilas and Vassilis G. Gorgoulis
Affiliation:
Keywords: Biomarkers, cardiovascular disease, inflammation, miRNAs.
Abstract: Cardiovascular diseases (CVDs) have become a predominant cause of death worldwide. Although CVDs encompass a variety of pathological conditions that affect the heart and blood vasculature, they can be classified into two major groups according to their basic pathophysiologic mechanisms, namely atherosclerosis and aneurysm formation. Increasing evidence implicates micro-RNAs (miRNAs or miRs) as vital factors both in the initiation and progression processes of CVDs. Some miRs have a promoting role in CVD development, while others have a protective role. Today, miRs have been shown to be potential biomarkers for several types of CVDs, while strategies targeting miRs are under consideration as potential tools for exploitation in therapeutic approaches for CVD treatments. In this review, we present the available data on the involvement of miRs in CVDs, focusing on their role as regulators of the inflammatory process as an initiating and driving component of CVDs.
Export Options
About this article
Cite this article as:
Kotsinas Athanassios, Sigala Fragkiska, Garbis D. Spiros, Galyfos Giorgos, Filis Konstantinos, Vougas Konstantinos, Papalampros Alexandros, Johnson E. Elizabeth, Chronopoulos Efstathios, Georgakilas G. Alexandros and Gorgoulis G. Vassilis, MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets, Current Medicinal Chemistry 2015; 22 (22) . https://dx.doi.org/10.2174/0929867322666150716113304
DOI https://dx.doi.org/10.2174/0929867322666150716113304 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Cardiovascular & Hematological Disorders-Drug Targets Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis
Current Pharmaceutical Design IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry Analysis of the Clinical Characteristics and Follow-up Study of Children with Cutaneous Polyarteritis Nodosa
Current Neurovascular Research CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design Meet Our Editor:
Current Cardiology Reviews Review of Trans-Atlantic Cardiovascular Best Medical Therapy Guidelines – Recommendations for Asymptomatic Carotid Atherosclerosis
Current Vascular Pharmacology Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
Current Vascular Pharmacology Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design Hybrid PET Imaging in Neurologic Disease: PET/MRI Rather than PET/CT
Current Medical Imaging The Rabbit as an Experimental and Production Animal: From Genomics to Proteomics
Current Protein & Peptide Science The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews The Role of Serum Calprotectin as a New Marker in Abdominal Aortic Aneurysms – A Preliminary Report
Current Pharmaceutical Biotechnology Calcium Channel Blockers - Benefits Upon Vascular Biology in Hypertensive Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Selectins as Targets in Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Docking and Virtual Screening to Identify PKC Agonists: Potentials in Anticancer Therapeutics
Current Computer-Aided Drug Design Psoriasis and Vascular Risk : An Update
Current Pharmaceutical Design